Skip to main content
. 2024 Mar 5;32(5):479–488. doi: 10.1038/s41431-023-01507-5

11. Laboratories must establish the assay limit of detection (LoD) and analytical sensitivity for all categories of variant types through appropriate validation.

12. The percentage neoplastic cell content assessment must be integral to tumour tissue analysis.

13. The neoplastic cell content percentage should be at least twice the validated LoD of the assay.